Recombinant Human Siglec-2/CD22 Fc Chimera Protein, CF 1968-SL-050 from R&D Systems, a Bio-Techne Brand

Product Specs
ItemRecombinant Human Siglec-2/CD22 Fc Chimera Protein, CF
CompanyR&D Systems, a Bio-Techne Brand
Price $420.00Supplier Page View Company Product Page
Catalog Number1968-SL-050
SpeciesHuman
Size50 ug
FormatLyophilized from a 0.2 µm filtered solution in PBS
Molecule NameSiglec-2/CD22
Purity>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
Molecular WeightObserved: 122-127 kDa, reducing conditions
Theoretical: 101.9 kDa (monomer)
ApplicationsBioactivity
Conjugate/TagUnconjugated
Source/Expression SystemNS0-derived Recombinant Human Siglec-2/CD22 Fc Chimera Protein, CF
StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution
NCBI Full Gene NameCD22 molecule
NCBI Gene AliasesSIGLEC-2, SIGLEC2

Add to Compare List

R&D Systems, a Bio-Techne Brand

614 McKinley Place N.E.

Minneapolis, Minnesota 55413

United States

Phone: 1 (800) 343-7475
1 (612) 379-2956

Fax: 1 (612) 656-4400

Company Profile

Website: http://www.rndsystems.com

(1) Sialic acid-modified der p 2 allergen exerts immunomodulatory effects on human PBMCsJ Allergy Clin Immunol GlobFebruary 1, 2024Keumatio Doungtsop BC, Nardini E, Kalay H, Versteeg SA, Lübbers J, van Barneveld G, Li ERJ, van Vliet SJ, van Ree R, de Jong EC, et al.Harbor, Me). The following Siglec-Fc chimeras (R&D Systems, Minneapolis, Minn) were used: Siglec-2–hFc (1968-SL-050), Siglec-3–hFc (1137-SL-050), Siglec-7–hFc (1138-SL-050), Siglec-9–hFc (1139-SL-050), and Siglec-10–hFc

(2) Massively parallel knock-in engineering of human T cellsNature biotechnologySeptember 1, 2023Dai X, Park JJ, Du Y, Na Z, Lam SZ, Chow RD, Renauer PA, Gu J, Xin S, Chu Z, et al.

(3) Efficient chimeric antigen receptor targeting of a central epitope of CD22The Journal of biological chemistryJuly 1, 2023Casey NP, Klee CH, Fåne A, Caulier B, Graczyk-Jarzynka A, Krawczyk M, Fidyt K, Josefsson SE, Köksal H, Dillard P, et al.

(4) CD19/CD22 bispecific chimeric antigen receptor‑NK‑92 cells are developed and evaluatedOncology lettersJune 1, 2023Kim H, Han M, Kim M, Kim H, Im HJ, Kim N, Koh KN.

(5) Small RNAs are modified with N-glycans and displayed on the surface of living cellsCellJune 10, 2021Ryan A. Flynn et al.GMBH,Cat# LS-3970 TRIzol LS,Thermo Fisher Scientific,Cat# 10296028 rec-hSiglec-2,R&D Systems,Cat# 1968-SL-050 rec-hSiglec-3,R&D Systems,Cat# 1137-SL-050 rec-hSiglec-Mag,R&D Systems,Cat# 8940-MG-050 rec-hSiglec-5,R&D Systems

(6) Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cellsNature medicineMay 1, 2021Singh N, Frey NV, Engels B, Barrett DM, Shestova O, Ravikumar P, Cummins KD, Lee YG, Pajarillo R, Chun I, et al.a Biacore T200 system. Briefly, recombinant human CD22 ECD-Fc was obtained from R&D systems (Cat. # 1968-SL-050). CD22-Fc was immobilized on a CM5 chip surface using standard amine coupling at a target density of

(7) Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T CellsCellAugust 22, 2019Dong MB, Wang G, Chow RD, Ye L, Zhu L, Dai X, Park JJ, Kim HR, Errami Y, Guzman CD, et al.(Lot: R44921),Novus,Cat#NBP2–13922 "Recombinant Human Siglec-2/CD22 Fc Chimera Protein, CF",R&D,Cat#1968-SL-050 GAPDH Antibody (clone: 6C5),Santa Cruz,Cat#sc-32233 anti-GFP,AbCam,Cat#ab290 Anti-Nucleolin antibody,AbCam,Cat#ab22758 ,, Bacterial

(8) Lectin nanoparticle assays for detecting breast cancer-associated glycovariants of cancer antigen 15-3 (CA15-3) in human plasmaPloS oneJanuary 1, 2019Terävä J, Tiainen L, Lamminmäki U, Kellokumpu-Lehtinen PL, Pettersson K, Gidwani K.

(9) CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapyNature medicineJanuary 1, 2018Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, Wolters P, Martin S, Delbrook C, Yates B, et al.

(10) Broad and direct interaction between TLR and Siglec families of pattern recognition receptors and its regulation by Neu1eLifeSeptember 3, 2014Chen GY, Brown NK, Wu W, Khedri Z, Yu H, Chen X, van de Vlekkert D, D'Azzo A, Zheng P, Liu Y.

(11) Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemiaBloodFebruary 14, 2013Haso W, Lee DW, Shah NN, Stetler-Stevenson M, Yuan CM, Pastan IH, Dimitrov DS, Morgan RA, FitzGerald DJ, Barrett DM, et al.

(12) Generation, affinity maturation, and characterization of a human anti-human NKG2D monoclonal antibody with dual antagonistic and agonistic activityJournal of molecular biologyDecember 31, 2008Kwong KY, Baskar S, Zhang H, Mackall CL, Rader C.

Be the First to Write a Review!

Recombinant Human Siglec-2/CD22 Fc Chimera Protein, CF from R&D Systems, a Bio-Techne Brand

R&D Systems, a Bio-Techne Brand

Citations (12)

Reviews

Recombinant Human Siglec-2/CD22 Fc Chimera Protein, CF from R&D Systems, a Bio-Techne Brand

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map